We are live on ! Find out more

OS Therapies Inc

OSTX

Market cap $46.8M

1.00 USD

+0.02

2.03%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

0.9800

-0.0200

2%

1 day

2.03%

5 days

-19.35%

1 month

-32.89%

3 months

-38.65%

6 months

-42.2%

Year to date

-25.37%

1 year

-45.05%

5 years

-60.16%

10 years

-60.16%

About: OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.

Employees: 5

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.7%

Neutral 93.3%

Negative 0%

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial

Leading Clinical Stage Oncology Company Now Able to Complete CMMA Submission to U.K's MHRA for Early Commercial Access and Trial Authorisation Grasonville, Maryland--(Newsfile Corp. - November 5, 2026) - OS Therapies, Inc . (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has completed the requalification of drug substance used in its Phase 2b trial of OST-HER2 (Herlystic™) in the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma.

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestones Company expects to complete early market access regulatory approval submissions for Herlystic™ ("OST-HER2" or "daznelimgene lisbac") in the U.S., U.K., Europe and Australia in the fourth quarter of 2026 Grasonville, Maryland--(Newsfile Corp. - October 19, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced the initial closing of a warrant exercise inducement and exchange offer that was made to nine accredited investors (the "Holders") that beneficially owned common stock purchase warrants (the "Existing Warrants") to exercise, or pre-fund the exercise of, their Existing Warrants for cash at a reduced exercise price of $1.30 per share (or $1.299 per share for a pre-funding). At the initial closing, seven Holders exercised, or pre-funded the exercise of, Existing Warrants to purchase an aggregate of 5,517,253 shares of common stock, resulting in a total of $7.2 million in gross proceeds to the Company, before deducting solicitation agent fees and other offering expenses payable by the Company.

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

Rubenstein Public Relations Named Agency of Record for OS Therapies

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rubenstein Public Relations (RPR), a leading full-service communications firm, announces it has been named the Agency of Record for OS Therapies, Inc. (NYSE American: OSTX), the world leader in gene-edited, Listeria-based cancer immunotherapies. Recently, OS Therapies announced that it has reached a critical point in achieving entry into the global market with access into the U.K national patient registry and UK Clinical Practice Research Datalink (CPRD) by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

Rubenstein Public Relations Named Agency of Record for OS Therapies

OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

Received notice for upcoming USDA meeting Company is reviewing strategic alternatives to monetize OS Animal Health ("OSAH") Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health subsidiary, OSAH received feedback from the U.S. Department of Agriculture (USDA) related to its submission to gain alignment on the commercial development pathway for OST-HER2 in the treatment of canine osteosarcoma. USDA provided guidance related to the OSAH's upcoming conditional licensure request in the areas of clinical efficacy, clinical safety, non-clinical and Chemistry, Manufacturing and Controls (CMC) as a prelude to commercialization.

OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment

OS Therapies Inc. (NYSE:OSTX) announced a statistically significant three-year overall survival benefit for patients treated with OST-HER2 in its Phase 2b trial.

OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients 72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006) Company preparing to complete submissions for early market access in the U.S., U.K., Europe and Australia WHO recently accepted the proprietary brand name Herlystic™ for OST-HER2 (daznelimgene lisbac).

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic™(OST-HER2; daznelimgene lisbac) Grasonville, Maryland--(Newsfile Corp. - October 1, 2026) - OS Therapies, Inc . (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced the appointment of Kerry Clem as Chief Commercial Officer (CCO) and Frank Knuettel II as Chief Financial Officer (CFO).

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announce that the World Health Organization has approved the proprietary name 'Herlystic' was approved by the World Health Organization (WHO) as the brand name for OST-HER2. The nonproprietary name daznelimgene lisbac for the ingredients in OST-HER2 was previously approved WHO.

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing Authorisation Application (CMAA) submission in the coming weeks and Phase 3 trial initiation in mid Q4/'26 following Phase 2b drug product requalification MHRA's SAM participants' recommendation to Project Orbis U.K. leadership to take the global regulatory leadership mantle with U.S. FDA and EMA, coupled with granting the Company access to U.K. national patient registry, the UK Clinical Practice Research Datalink (CPRD) to strengthen comparator data while Phase 3 is ongoing to further improve interpretability of data during early market access phase Since 2021, 29 MHRA-led products have been approved by U.S. FDA via Project Orbis Company continues to engage with U.S. FDA on the non-Orbis Accelerated Approval route after successful Type C Statistical Methods Meeting that resulted in alignment on amended Phase 3 study design as buildout of OST-400 natural history database expands to include U.K. national patient registry data and Company awaits FDA decisions on RMAT, Rolling Review and CNPV ahead of the pending Q4/'26 completion of its ongoing BLA filing initiated in Q1/'26 BLAs granted via Project Orbis are eligible to receive Priority Review Vouchers (PRVs) and may also be granted via the Accelerated Approval Program Patient previously reported as lost to follow-up confirmed to be alive New York, New York and Rockville, Maryland--(Newsfile Corp. - September 21, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided an update on global early market access regulatory coordination efforts being led by the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) following the Company's acceptance of MHRA's request to become the lead regulatory agency to drive early market access for OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program") under Project Orbis. Project Orbis is the U.S. Food & Drug Administration (FDA) Oncology Center of Excellence (OCE) initiative started in May 2019 to provide a framework for concurrent submission and review of oncology products among international partners.

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial After successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize regulatory review with FDA and EMA CBER recently re-opened Project Orbis to foreign-sponsored U.S. companies only New York, New York and Rockville, Maryland--(Newsfile Corp. - September 17, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has achieved incremental alignment with the U.S. Food & Drug Administration (FDA) in the Company's pursuit of a Biologics License Application (BLA) for OST-HER2 in the prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program"). The Company aligned with the FDA on the use of the proposed adaptive design agreed upon with the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) for the pending Phase 3 clinical trial that is expected to commence in the fourth quarter of 2026.

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

See News Rankings

Price charts implemented using Lightweight Charts™